drugset
drugset / Trial / NCT06663176

Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa)

NCT06663176 ↗

Phase 1/2 Active not recruiting 60 enrolled Thirty Respiratory Limited
RandomizedSingle-groupOpen-labelTreatment

Summary

A Phase 1/2a, Multi-Centre, Randomised, Open-label study to assess the safety, tolerability, PK, and efficacy of RESP30X in Adult NCFB participants with confirmed high-titre respiratory PPMs.

Timeline

Start
2024-10-16
Primary completion
2028-02-05
Completion
2028-05-05

Drugs

EvaluationDrugModalityDoseRoute
Subject RESP302 Unknown — Inhaled
Subject RESP303 Unknown — Inhaled

Indications

bronchiectasis